What is the primary reason for BDX's segment reorganization?

BDX reorganized its organizational units into five worldwide business segments to align strategic businesses that are managed separately because each one develops, manufactures, and markets distinct products and services. This is intended to provide better focus and potentially improve investor understanding of the company's diverse operations.

What is happening with the Life Sciences segment?

BDX has entered into an agreement to combine its Biosciences and Diagnostic Solutions business (which constitutes the Life Sciences segment) with Waters Corporation. Subsequent to this separation and combination, the Life Sciences segment will be eliminated from BD's segment reporting.

Will the segment reorganization impact the company's products or services?

The filing states that the segment reorganization did not affect the principal product lines of any organizational unit. The changes are primarily in how the company reports and manages its businesses.

Where can I find historical financial information under the new segment structure?

BDX has furnished recast historical segment revenues for fiscal year 2025 and corresponding prior year periods as Exhibit 99.1, presented in accordance with the new segment structure. This exhibit also contains details on non-GAAP measures.

BDX 8-K: Regulation FD

Summary

Becton Dickinson and Company (BDX) has announced a significant organizational restructuring, effective October 1, 2025, consolidating its operations into five distinct worldwide business segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences. This move aims to better align strategic business units that develop, manufacture, and market unique products and services. While the core product lines remain unchanged, this realignment is designed to enhance operational focus and potentially improve reporting clarity for investors moving forward. Of particular note for investors is the planned combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation, which is expected to result in the elimination of the Life Sciences segment from future reporting. This divestiture/combination will leave BD with four primary reportable segments. The company has furnished recast historical segment revenues for fiscal year 2025 and prior periods, presented under the new segment structure, to aid investors in understanding the historical performance in light of these changes. Investors should pay close attention to the details of the Life Sciences divestiture and the performance of the remaining four segments.

Key Highlights

1BDX has reorganized into five worldwide business segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences, effective October 1, 2025.
2This reorganization groups strategic business units with distinct product lines and market focuses.
3The company is planning to combine its Life Sciences segment (Biosciences and Diagnostic Solutions) with Waters Corporation.
4Following the combination with Waters Corporation, the Life Sciences segment will be eliminated, leaving four primary reportable segments for BDX.
5BDX has furnished recast historical segment revenues for fiscal year 2025 and prior periods reflecting the new segment structure.
6The furnished financial information includes non-GAAP measures, with details provided in Exhibit 99.1.

BECTON DICKINSON & CO 8-K Report, Regulation FD Disclosure (Feb 5, 2026)

Summary

Key Highlights

Frequently Asked Questions